Cipla gains on launching RT-PCR test kit `ViraGen` for COVID-19 in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Cipla is currently trading at Rs. 912.85, up by 8.80 points or 0.97% from its previous closing of Rs. 884.15 on the BSE.
The scrip opened at Rs. 906.00 and has touched a high and low of Rs. 913.05 and Rs. 905.00 respectively. So far 7287 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 966.00 on 20-Apr-2021 and a 52 week low of Rs. 595.00 on 20-May-2020.
Last one week high and low of the scrip stood at Rs. 920.95 and Rs. 870.00 respectively. The current market cap of the company is Rs. 72911.04 crore.
The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.
Cipla has launched a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems. ViraGen is the company’s third offering in the Covid-19 testing segment. It already has partnerships for antibody detection kit and antigen test kits.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19. ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems and marketed and distributed by Cipla through its expansive distribution network across the country.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
